PortfoliosLab logoPortfoliosLab logo
ABSI vs. ABCL
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ABSI vs. ABCL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Absci Corporation (ABSI) and AbCellera Biologics Inc. (ABCL). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ABSI vs. ABCL - Yearly Performance Comparison


2026 (YTD)20252024202320222021
ABSI
Absci Corporation
-14.04%33.21%-37.62%100.00%-74.39%-62.02%
ABCL
AbCellera Biologics Inc.
2.05%16.72%-48.69%-43.63%-29.16%-10.79%

Fundamentals

Market Cap

ABSI:

$451.83M

ABCL:

$1.04B

EPS

ABSI:

-$0.82

ABCL:

-$0.49

PS Ratio

ABSI:

150.70

ABCL:

13.88

PB Ratio

ABSI:

2.38

ABCL:

1.08

Total Revenue (TTM)

ABSI:

$2.80M

ABCL:

$75.13M

Gross Profit (TTM)

ABSI:

-$36.85M

ABCL:

-$36.22M

EBITDA (TTM)

ABSI:

-$112.98M

ABCL:

-$126.64M

Returns By Period

In the year-to-date period, ABSI achieves a -14.04% return, which is significantly lower than ABCL's 2.05% return.


ABSI

1D
8.70%
1M
9.49%
YTD
-14.04%
6M
-1.32%
1Y
19.52%
3Y*
19.68%
5Y*
10Y*

ABCL

1D
6.40%
1M
-3.32%
YTD
2.05%
6M
-30.62%
1Y
56.50%
3Y*
-22.65%
5Y*
-35.27%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ABSI vs. ABCL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABSI
ABSI Risk / Return Rank: 5151
Overall Rank
ABSI Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
ABSI Sortino Ratio Rank: 5757
Sortino Ratio Rank
ABSI Omega Ratio Rank: 5353
Omega Ratio Rank
ABSI Calmar Ratio Rank: 4848
Calmar Ratio Rank
ABSI Martin Ratio Rank: 4747
Martin Ratio Rank

ABCL
ABCL Risk / Return Rank: 6565
Overall Rank
ABCL Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
ABCL Sortino Ratio Rank: 7070
Sortino Ratio Rank
ABCL Omega Ratio Rank: 6565
Omega Ratio Rank
ABCL Calmar Ratio Rank: 6262
Calmar Ratio Rank
ABCL Martin Ratio Rank: 5959
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ABSI vs. ABCL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Absci Corporation (ABSI) and AbCellera Biologics Inc. (ABCL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ABSIABCLDifference

Sharpe ratio

Return per unit of total volatility

0.22

0.73

-0.51

Sortino ratio

Return per unit of downside risk

1.01

1.61

-0.60

Omega ratio

Gain probability vs. loss probability

1.12

1.18

-0.06

Calmar ratio

Return relative to maximum drawdown

0.21

0.93

-0.72

Martin ratio

Return relative to average drawdown

0.39

1.83

-1.44

ABSI vs. ABCL - Sharpe Ratio Comparison

The current ABSI Sharpe Ratio is 0.22, which is lower than the ABCL Sharpe Ratio of 0.73. The chart below compares the historical Sharpe Ratios of ABSI and ABCL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ABSIABCLDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.22

0.73

-0.51

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.53

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.36

-0.60

+0.24

Correlation

The correlation between ABSI and ABCL is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Dividends

ABSI vs. ABCL - Dividend Comparison

Neither ABSI nor ABCL has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ABSI vs. ABCL - Drawdown Comparison

The maximum ABSI drawdown since its inception was -96.20%, roughly equal to the maximum ABCL drawdown of -96.72%. Use the drawdown chart below to compare losses from any high point for ABSI and ABCL.


Loading graphics...

Drawdown Indicators


ABSIABCLDifference

Max Drawdown

Largest peak-to-trough decline

-96.20%

-96.72%

+0.52%

Max Drawdown (1Y)

Largest decline over 1 year

-54.00%

-54.94%

+0.94%

Max Drawdown (5Y)

Largest decline over 5 years

-94.35%

Current Drawdown

Current decline from peak

-90.10%

-94.07%

+3.97%

Average Drawdown

Average peak-to-trough decline

-84.81%

-83.30%

-1.51%

Ulcer Index

Depth and duration of drawdowns from previous peaks

28.35%

27.87%

+0.48%

Volatility

ABSI vs. ABCL - Volatility Comparison

Absci Corporation (ABSI) has a higher volatility of 29.96% compared to AbCellera Biologics Inc. (ABCL) at 12.03%. This indicates that ABSI's price experiences larger fluctuations and is considered to be riskier than ABCL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ABSIABCLDifference

Volatility (1M)

Calculated over the trailing 1-month period

29.96%

12.03%

+17.93%

Volatility (6M)

Calculated over the trailing 6-month period

70.05%

53.26%

+16.79%

Volatility (1Y)

Calculated over the trailing 1-year period

89.36%

78.17%

+11.19%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

96.13%

66.57%

+29.56%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

96.13%

69.65%

+26.48%

Financials

ABSI vs. ABCL - Financials Comparison

This section allows you to compare key financial metrics between Absci Corporation and AbCellera Biologics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M350.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
650.00K
44.85M
(ABSI) Total Revenue
(ABCL) Total Revenue
Values in USD except per share items